講演情報
[WS01-15-P]Sublingual immunization with inactivated enterovirus A71 induced pathogen-specific mucosal and systemic protective antibody responses
○Meito Shibuya1,2, Tomonori Machita1, Tomoyuki Yamamoue1, Satoshi Koike3, Kyousuke Kobayashi3, Seiya Yamayoshi4,5, Hiroshi Kiyono1,7,8, Kohtaro Fujihashi1,6,9,10 (1.Department of Human Mucosal Vaccinology, Chiba University Hospital, and Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, 2.Vaccine R&D Laboratory, Vaccine Business Division, Shionogi & Co., Ltd., 3.Neurovirology Project, Department of Diseases & Infection, Tokyo Metropolitan Institute of Medical Science, 4.Div. Virology & Intern. Res. Ctr Infect. Dis., Inst. Med. Sci., and Univ. Tokyo Pandemic Prep., Infect. Adv. Res. Ctr (UTOPIA), The University of Tokyo, 5.The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, 6.Division of Infectious Disease Vaccine R&D, Research Institute of Disaster Medicine, Chiba University, 7.Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine, San Diego, CA, USA, 8.Future Medicine Education and Research Organization, Mucosal Immunology and Allergy Therapeutics, Institute for Global Prominent Research, Chiba University, 9.Division of Mucosal Vaccines, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, 10.Department of Pediatric Dentistry, The University of Alabama at Birmingham, Birmingham AL, USA)
キーワード：
Enterovirus A71、sublingual vaccine、inactivated vaccine
閲覧にはパスワードが必要です
ログイン
または